Corbus Pharmaceuticals Holdings, Inc. (CRBP)
After hours:
| Previous close | 0.3003 |
| Open | 0.3038 |
| Bid | 0.2902 x 2900 |
| Ask | 0.3000 x 1000 |
| Day's range | 0.2903 - 0.3038 |
| 52-week range | 0.2080 - 2.2900 |
| Volume | |
| Avg. volume | 1,582,980 |
| Market cap | 37.36M |
| Beta (5Y monthly) | 2.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Corbus Presents Latest Preclinical Data for CRB-601 at the New York Academy of Sciences Frontiers in Cancer Immunotherapy Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced that new preclinical data for CRB-601 are being presented today in an oral presentation at the New York Academy of Sciences (NYAS) Frontiers in Cancer Immunotherapy Conference in New York, NY.
- PR Newswire
Corbus Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, today provided a corporate update and reported financial results for the first quarter of 2022.
- PR Newswire
Corbus Presents First Preclinical Data for CRB-601 at the American Association for Cancer Research (AACR) Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), an immunology company, announced today the first preclinical data for CRB-601 are being presented in a poster at the American Association for Cancer Research (AACR) Annual Meeting being held from April 8-13, 2022, in New Orleans, LA. CRB-601 is a potent and selective αvb8 integrin monoclonal antibody designed to block the activation of TGFb in the local tumor microenvironment. TGFb is thought to be the only ligand
